Last $0.69 USD
Change Today +0.0098 / 1.44%
Volume 131.6K
CYCC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Open
$0.68
Previous Close
$0.68
Day High
$0.72
Day Low
$0.68
52 Week High
01/9/14 - $4.84
52 Week Low
12/17/14 - $0.61
Market Cap
15.9M
Average Volume 10 Days
880.8K
EPS TTM
$-0.88
Shares Outstanding
23.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (CYCC)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/26/14
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $713.4K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $463.1K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $442.4K
Compensation as of Fiscal Year 2013.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on Preferred Stock , Payable on February 1, 2015

On December 3, 2014, the Board of Directors of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the Company’s 6% Convertible Exchangeable Preferred Stock. The cash dividend will be payable on February 1, 2015 and paid on February 2, 2015 to the holders of record of the Preferred Stock as of the close of business on January 5, 2015.

Cyclacel Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter Ended September 30, 2014

Cyclacel Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter ended September 30, 2014. For the quarter, the company reported total revenues of $735,000 against $309,000 a year ago. Operating loss was $5,670,000 against $5,795,000 a year ago. Loss from continuing operations before taxes was $5,661,000 against $5,746,000 a year ago. Net loss from continuing operations was $4,911,000 or $0.22 per diluted share against $5,016,000 or $0.32 per diluted share a year ago. Net loss applicable to common shareholders was $4,957,000 or $0.22 per diluted share against $5,728,000 or $0.32 per diluted share a year ago. The reported $15 million of net cash used in operating activities.

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 11, 2014

Cyclacel Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $0.69 USD +0.0098

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies
 

Industry Analysis

CYCC

Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.